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a b s t r a c t
To assess the association between inﬂuenza immunization and subsequent diagnosis of group A streptococcus (GAS)-illness in Army recruits during inﬂuenza seasons 2002–2006. A case–control study was
employed with cases as trainees with outpatient GAS diagnosis (ICD-9-CM codes: 034.0, 035, 038.0, 041.01,
320.2, 390–392, 482.31) during the inﬂuenza season, and controls as trainees with no outpatient GAS diagnosis during the inﬂuenza season. Primary exposure was inﬂuenza immunization during 1st September
to 30th April of each season. Estimated protective effects of inﬂuenza immunization against GAS-illness
ranged from 50% to 77%. A strong protective effect was suggested for Army trainee inﬂuenza immunization
on the diagnosis of GAS-illness.
© 2008 Elsevier Ltd. All rights reserved.

1. Introduction
Group A streptococcus (GAS) infections are often asymptomatic;
and of those that are clinically signiﬁcant, most are expressed as
acute, febrile tonsillo-pharyngitis (i.e., strep throat) that is transiently debilitating [1]. However, some virulent GAS strains cause
invasive diseases that can be severe (e.g., peritonsillar abscess) and
even life threatening (e.g., pneumonia, necrotizing fasciitis, toxic
shock). Finally, some “rheumatogenic” strains of GAS have delayed
clinical effects that are acutely debilitating (e.g., acute rheumatic
fever) and often chronically disabling (e.g., valvular heart disease)
[2–4].
Since the 1950s, at various military training installations, benzathine penicillin G (BPG) has been given to non-allergic trainees
before they begin recruit training. This process of tandem prophylaxis (administering prophylaxis to new incoming recruits) is
designed to prevent the introduction of virulent strains of GAS into
recruit camps and to protect new recruits from acquiring GAS infections during the ﬁrst few weeks of training [3,4]. Although BPG is
effective in reducing the risk for GAS infection, continued outbreaks
highlight the need for additional preventive measures.
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New military recruits are a sample of the young adult population of the United States and its territories who enter the training
installation on a daily basis. Therefore, numerous and varied respiratory pathogens are continuously ‘seeded’ into, and co-circulate
in, recruit populations, particularly during the fall-winter seasons.
Co-circulating respiratory pathogens may interact through many
mechanisms. The most studied and best-documented interactions
are between inﬂuenza and bacterial respiratory pathogens, including GAS [5–8]. Not surprisingly, during past inﬂuenza pandemics,
streptococcal pneumonias caused a substantial number of deaths,
including among young adults [5].
To counter the threats of inﬂuenza and GAS-related diseases,
all new recruits are immunized with the current year’s inﬂuenza
vaccine at all military installations, and routinely administered
BPG prophylaxis against GAS at Forts Benning, Leonard Wood, and
Sill, beginning basic combat training (BCT). The aim of the current
study was to assess the effects, if any, of inﬂuenza immunization
on GAS-related illnesses, in perennially high risk settings and seasons, using routinely collected surveillance data. To address this
aim, a case–control study design was employed, in which streptococcal illnesses diagnosed among U.S. Army trainees were assessed
in relation to their records of inﬂuenza immunization status in one
of the four recent inﬂuenza seasons.
2. Methods
The surveillance period encompassed four inﬂuenza seasons
deﬁned as 1st September to 30th April of 2002–2003, 2003–2004,
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2004–2005, and 2005–2006. The surveillance population included
all active component members of the U.S. Army who entered as
trainees anytime during the surveillance period at a BCT site: Fort
(Ft.) Benning, GA; Ft. Jackson, SC; Ft. Knox, KY; Ft. Leonard Wood,
MO; or Ft. Sill, OK. Trainees were followed from entry into training until 30th April of any given year. All study data were captured
from the Defense Management Surveillance System (DMSS), a public health surveillance database that includes routinely collected
data on all medical encounters at military treatment facilities, as
well as demographic data for military service members [9].
A case was deﬁned as the occurrence of at least one outpatient diagnosis of a GAS-related illness (ICD-9-CM codes: 034.0,
035, 038.0, 041.01, 320.2, 390–392, 482.31), a minimum of 30 days
(the estimated protective effect from a single dose of BPG) after
the start of BCT [10]. The latter criterion was employed to avoid
bias that may be introduced into the study results due to the selective administration of BPG at Fts. Benning, Leonard Wood, and Sill.
To note, other evidence suggests inadequate serum levels of BPG
after 14 days of administration [11]. However, identical results were
produced when repeating our analysis using a shorter window of
14 days. Each case was matched to a maximum of four trainees
with no outpatient GAS-related illness diagnosis (i.e., ‘controls’),
by unit identiﬁcation code (UIC), a code speciﬁc to each BCT site
and individual training unit.
Exposure was deﬁned as the receipt, or the lack thereof, of an
inﬂuenza immunization a minimum of 14 days (the estimated time
to development of protective antibodies after immunization) prior
to the date of diagnosis [12]. As multiple vaccines are typically
administered to all new recruits, trainees with no documented
vaccinations were excluded from the study to minimize misclas-

siﬁcation due to missing records (n = 5, 400, 3.7% of records). To
note, BCT is a 9-week training program and is the recruits’ ﬁrst
encounter at a military installation/post as a military service member. An inﬂuenza immunization administered to a recruit would
have occurred at a BCT post.
Statistical analysis was performed using SAS version 9.1.3 (SAS
Institute, Cary, NC). Cases and controls were assessed with respect
to demographic/military characteristics and exposure to inﬂuenza
immunization, by inﬂuenza season, using McNemar’s 2 tests. Conditional logistic regression, matched by UIC, was used to evaluate
the effect of inﬂuenza immunization adjusted for independent
predictors of GAS-illness and/or inﬂuenza vaccination reported in
the literature. Covariates included age, gender, and month of entry
into service (proxy for total number of recruits on post) [13–15].
P < 0.05 for a two-tailed test was considered statistically signiﬁcant.
3. Results
One thousand and ninety-eight GAS-illness cases and 4370 controls were identiﬁed over the 2002 through 2006 inﬂuenza seasons.
Across seasons, the median of the distribution of months in which
GAS-related illnesses was documented among the unexposed
recruits (i.e., unimmunized), December, was several months earlier
than that documented among the exposed recruits (i.e., immunized), February. Stratiﬁed by season, GAS cases had a signiﬁcantly
lower odds than controls to have received an inﬂuenza immunization in both crude and adjusted (i.e., for age, gender, month of entry
into military service, and UIC) analyses (Table 1). The estimated
protective effects of inﬂuenza immunization against GAS-illness
ranged from 50% (2002–2003 season) to 77% (2005–2006 season).

Table 1
Crude and adjusted odds ratio (OR) for GAS-illness to have received inﬂuenza vaccine, by inﬂuenza seasona
OR (95% CI)

Adjusted OR (95% CI)b

715 (62.9)
421 (37.1)

0.59 (0.44–0.80)
Reference

0.50 (0.37–0.68)
Reference

251 (72.1)
97 (27.9)

1215 (87.9)
168 (12.2)

0.33 (0.25–0.45)
Reference

0.26 (0.19–0.36)
Reference

Yes
No

112 (59.3)
77 (40.7)

633 (83.7)
123 (16.3)

0.22 (0.15–0.32)
Reference

0.14 (0.09–0.22)
Reference

Yes
No

198 (72.3)
76 (27.7)

971 (88.7)
124 (11.3)

0.25 (0.17–0.37)
Reference

0.23 (0.15–0.35)
Reference

Inﬂuenza season

Inﬂuenza vaccine

GAS cases n (%)

2002–2003

Yes
No

152 (53.0)
135 (47.0)

2003–2004

Yes
No

2004–2005
2005–2006

Controls n (%)

Note: CI, conﬁdence interval; GAS, group A streptococcus; OR, odds ratio; UIC, unit identiﬁcation code.
a
Case deﬁned as at least one occurrence of ICD-9-CM codes 034.0, 035, 038.0, 041.01, 320.2, 390–392, 482.31.
b
Adjusted for sex, age, month of service entry, and UIC.

Table 2
Crude and adjusted odds ratio for GAS-illness over four inﬂuenza seasonsa
GAS cases (n = 1098) n (%)

Controls (n = 4370) n (%)

OR (95% CI)

Adjusted OR (95% CI)b

Inﬂuenza
Vaccine
Sex

Yes
No
Male
Female

713 (64.9)
385 (35.1)
912 (83.1)
186 (16.9)

3534 (80.9)
836 (19.1)
3530 (80.8)
840 (19.2)

0.40 (0.35–0.47)
Reference
1.22 (1.00–1.49)
Reference

0.34 (0.29–0.40)
Reference
1.28 (1.04–1.57)
Reference

Age

17–19
20–24
25–29
30–35

576 (52.5)
435 (39.6)
65 (5.9)
22 (2.0)

2139 (48.9)
1667 (38.2)
425 (9.7)
139 (3.2)

1.73 (1.09–2.74)
1.67 (1.05–2.66)
0.98 (0.58–1.65)
Reference

1.62 (1.01–2.59)
1.54 (0.96–2.48)
0.89 (0.52–1.52)
Reference

Inﬂuenza
Season

2002–2003
2003–2004
2004–2005
2005–2006

287 (26.1)
348 (31.7)
189 (17.2)
274 (24.9)

1136 (26.0)
1383 (31.7)
756 (17.3)
1095 (25.1)

1.00 (0.79–1.26)
1.00 (0.80–1.24)
1.00 (0.78–1.28)
Reference

0.80 (0.63–1.03)
1.09 (0.87–1.38)
0.92 (0.71–1.19)
Reference

Characteristic

Note: CI, conﬁdence interval; GAS, group A streptococcus; OR, odds ratio; UIC, unit identiﬁcation code.
a
Case deﬁned as at least one occurrence of ICD-9-CM codes 034.0, 035, 038.0, 041.01, 320.2, 390–392, 482.31.
b
Adjusted for sex, age, season, month of service entry, and UIC.
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Collapsed over the four inﬂuenza seasons considered (Table 2),
GAS cases had a 66% lower odds of having received an inﬂuenza
immunization than controls (adjusted odds ratio [aOR] 0.34; 95%
conﬁdence interval [CI], 0.29–0.40). Approximately 65% of all cases
and 81% of all controls had documented inﬂuenza immunizations during the combine inﬂuenza seasons. Of the 1221 with no
documented inﬂuenza immunization, 26 (2.1%) had documented
reasons for missing immunization; 15 (1.2%) received medical
exceptions (e.g., egg allergy), and 11 (0.9%) did not receive immunization due to administrative orders (e.g., termination of military
service). Adjusted for immunization status, and the aforementioned covariates, males had a greater odds for a GAS-illness
diagnosis than females (aOR 1.28; 95% CI, 1.04–1.57). Age was also
an independent predictor for GAS-illness, with trainees younger
than 25 years demonstrating nearly twice the odds for a diagnosis
than those 30 years and older (aOR 1.62; 95% CI, 1.01–2.59).

4. Discussion
A strong protective effect was suggested for BCT inﬂuenza
immunization on the diagnosis of a GAS-illness, in a young and
healthy military population (aOR 0.34; 95% CI, 0.29–0.40). This
association was consistent across four recent inﬂuenza seasons.
The results suggest that inﬂuenza immunization may decrease
the odds of acquiring, and/or change the clinical expression
of, GAS infections during recruit training. Epidemiologic and
clinical interactions between inﬂuenza and bacterial respiratory
pathogens are well documented in the literature, suggesting biologic plausibility for the measured beneﬁcial effect of inﬂuenza
immunization on GAS-illness in the current study. However, due
to several study limitations, these ﬁndings must be interpreted
cautiously.
The case deﬁnition employed in the current study was based
on routinely kept medical surveillance records and thus the speciﬁc criteria for GAS diagnosis (i.e., clinical vs. laboratory) are
unknown. The lack of laboratory conﬁrmation may raise concern
with regard to possible misclassiﬁcation in that a clinician may
erroneously assign a GAS diagnosis based on clinical presentation rather than diagnostic test results [16]. However, previously
published work suggests that only a minority, ∼2%, of clinicians
use clinical criteria alone to diagnose GAS and this proportion
may be decreasing over time with the increasing availability
of highly sensitive, easy to use point-of-care tests (e.g., rapid
antigen-detection test) [17,18]. Furthermore, we do not expect clinicians to differentially diagnose GAS based on a trainee’s inﬂuenza
immunization status (i.e., exposure). The employment of routinely
reported medical administrative records (i.e., ICD-9-CM codes)
introduces the possibility of case-misclassiﬁcation due to data
entry and miscoding errors. The use of routinely reported medical
administrative records also introduces the possibility of exposure
misclassiﬁcation due to data entry and miscoding errors in vaccine
administration. Furthermore, many of the other immunizations
administered at the start of recruit training may play a role in
the observed effect between inﬂuenza vaccine and GAS-related illnesses. A high prevalence of unimmunized recruits (i.e., 11–47%)
was documented during the current study. Given that U.S. Army
policy dictates inoculation with the current year’s inﬂuenza vaccine to all non-allergic service members, the latter prevalence
may reﬂect incomplete or inaccuracies in reporting [19]. However,
the surveillance period corresponding to the ‘inﬂuenza season’
employed in the current study, September through April, may
have resulted in the capture of substantial numbers of recruits
who entered service after the ‘prior year’s’ inﬂuenza vaccine was
removed from use, but prior to the ‘next year’s’ vaccine hav-
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ing become available. If these recruits had not been targeted
for ‘catch up’ with the current year’s vaccine, they would have
remained unimmunized against inﬂuenza throughout their BCT
period.
Another potential limitation in the interpretation of the results
of the current study is related to the ecologic nature of the BPG
prophylaxis assessment. BPG prophylaxis status was based on
installation policy, not on individual record. Therefore, true GASillness cases may have been excluded from the study by the 30-day
latency case-deﬁnition criterion. Furthermore, tandem prophylaxis
with BPG not only protects recipients from acquiring GAS infections
during the ﬁrst few weeks of training but also prevents the seeding
of GAS strains into the recruit population. To the extent that recruit
camps are epidemiologically closed – hence, isolated from outside
sources of GAS – tandem prophylaxis would lower risk of streptococcal illnesses during the entire basic training period. If trainees
who received inﬂuenza immunizations were more likely than others to receive BPG, then the apparent association between inﬂuenza
immunization and GAS-related illnesses could reﬂect he prolonged,
population-level effects of tandem BPG prophylaxis [20]. However, there was no reason to have expected an association between
BPG prophylaxis and inﬂuenza immunization. Furthermore, it is
presumed that stratiﬁcation by UIC would accommodate this association had it been extant.
In conclusion, the strong protective effect of Army trainee
inﬂuenza immunization on the odds of GAS-illness diagnosis,
measured in the current study, is both biologically plausible and relevant to current clinical military practice. Many epidemiologic and
clinical interactions have been documented between respiratory
pathogens—including, for example, between inﬂuenza and GAS
[5,8]. Given this synergism among various pathogens, the effects
of agent-speciﬁc interventions may also be synergistic (i.e., greater
in scope and magnitude than preventing agent-speciﬁc diseases
alone) [8]. A prospective study with immunization status veriﬁcation and laboratory conﬁrmed GAS-illness diagnosis is necessary to
validate or refute these ﬁndings.
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